Clinical Study

Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation

Table 4

Medication after kidney transplantation.

Time after transplantation01 month12 months24 months36 months
Available data2727191511

Calcium carbonate19 (70%)13 (48%)4 (21%)2 (13%)0 (0%)
Vitamin D analogues21 (78%)18 (67%)7 (37%)6 (40%)4 (36%)
 Cholecalciferol1 (4%)0 (0%)1 (5%)0 (0%)1 (9%)
 Alfacalcidol13 (48%)11 (41%)3 (16%)4 (27%)2 (18%)
 Calcitriol8 (30%)7 (26%)3 (16%)2 (13%)2 (18%)
Bisphosphonate16 (59%)12 (63%)10 (67%)8 (73%)
Immunosuppression
 Prednisone27 (100%)19 (100%)15 (100%)11 (100%)
 CNI25 (93%)17 (89%)12 (80%)8 (73%)
 Mycophenolate27 (100%)16 (84%)13 (87%)9 (82%)
 Azathioprine0 (0%)1 (5%)2 (13%)2 (18%)
 mTOR inhibitor2 (7%)2 (11%)3 (20%)3 (27%)

CNI: calcineurin inhibitors; mTOR: mammalian target of rapamycin; results are expressed as count (% of the available data at that point in time).